Home › Ovarian Cancer › Wisconsin › Madison
Ovarian Cancer clinical trials in Madison, WI
13 studies for Ovarian Cancer are looking for participants at sites in and around Madison (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecruitingPhase 2
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- University of Wisconsin Carbone Cancer Center, Madison
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
RecruitingPhase 2
- UW Health Carbone Cancer Center, Madison
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
RecruitingPhase 2
- Research Site, Madison
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
RecruitingPhase 3
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RecruitingPhase 1
- University of Wisconsin - Carbone Cancer Center, Madison
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
RecruitingPhase 2
- University of Wisconsin, Madison
Cognitive Impact of Neoadjuvant Chemotherapy for Gynecologic Cancers
RecruitingObservational study
- UW Carbone Cancer Center, Madison
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
RecruitingPhase 2/3
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Recruiting
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
RecruitingPhase 2
- University of Wisconsin - Carbone Cancer Center - University Hospital, Madison
Lead-212 PSV359 Therapy for Patients With Solid Tumors
RecruitingPhase 1/2
- University of Wisconsin, Madison
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
RecruitingPhase 1
- University of Wisconsin Carbone Cancer Center, Madison
About Ovarian Cancer
Ovarian cancer is a cancerous tumor that forms in the tissues of an ovary. The ovaries are a pair of female reproductive glands that make eggs and female hormones.
More about Ovarian Cancer on MedlinePlus
Ovarian Cancer trials in other cities
- Houston, TX89 studies
- New York City, NY69 studies
- Boston, MA61 studies
- Los Angeles, CA50 studies
- Nashville, TN49 studies
- Arlington, VA46 studies
- Philadelphia, PA44 studies
- Columbus, OH39 studies
- St. Louis, MO38 studies
- Chicago, IL36 studies
- San Antonio, TX31 studies
- Cleveland, OH30 studies
Other studies in Madison
- Prostate Cancer29 studies
- Colorectal Cancer22 studies
- Breast Cancer22 studies
- Metastatic Cancer21 studies
- Non-Small Cell Lung Cancer16 studies
- Acute Myeloid Leukemia16 studies
- Melanoma15 studies
- Cancer (all types)14 studies
- Stomach Cancer11 studies
- Lung Cancer10 studies
- Pancreatic Cancer10 studies
- Multiple Myeloma9 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.